Skip to main content
Premium Trial:

Request an Annual Quote

Baylor Wins DoD Funding for Breast Cancer Tumor Profiling

NEW YORK (GenomeWeb News) – Baylor College of Medicine scientists plan to use two new Department of Defense grants to study genomic changes involved in breast cancer tumor formation and therapeutic targets based on those alterations.

The roughly $780,000 in total funding to two researchers at BCM's Lester and Sue Smith Breast Center, Assistant Professor Xiaosong Wang and Associate Professor Rachel Schiff, was awarded under DoD's Breast Cancer Research Program.

"Using computational technology, we will zoom into the genome to identify the key changes that control the cancer cells," Wang said.

The researchers will use publicly available datasets and a novel bioinformatics tool Wang developed to analyze the data from a human tumor genome sequence and to identify the operations of those genetic changes.

"The new technology can substantially improve and advance the interpretation of these data, incorporating significant new data sets immediately reanalyzing and updating," said Schiff.

Some of the genetic changes the researchers identify will make "attractive drug targets," Wang said, explaining that some of these targets may already have been developed for other diseases and could be repurposed for breast cancer studies, while others may lead to new drugs.

Schiff also said that "down the road, these new targets could be translated into diagnostic assays as well" that could be developed at BCM.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.